Corentin Schepkens
Overview
Explore the profile of Corentin Schepkens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reguiai Z, Ghislain P, Moulin P, Baudier E, Schepkens C, Sintes M, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(3):707-719.
PMID: 39979765
Introduction: The effectiveness of psoriasis treatment is assessed by standardized tools such as the Dermatology life Quality Index (DLQI) and Psoriasis Area Severity Index (PASI). However, discrepancies between patients and...
2.
Mauri F, Schepkens C, Lapouge G, Drogat B, Song Y, Pastushenko I, et al.
Nat Cancer
. 2022 Feb;
2(11):1152-1169.
PMID: 35122061
The nongenetic mechanisms required to sustain malignant tumor state are poorly understood. During the transition from benign tumors to malignant carcinoma, tumor cells need to repress differentiation and acquire invasive...
3.
Vara-Perez M, Rossi M, Van den Haute C, Maes H, Sassano M, Venkataramani V, et al.
EMBO J
. 2021 May;
40(10):e106214.
PMID: 33932034
BNIP3 is a mitophagy receptor with context-dependent roles in cancer, but whether and how it modulates melanoma growth in vivo remains unknown. Here, we found that elevated BNIP3 levels correlated...
4.
Dallons M, Alpan E, Schepkens C, Tagliatti V, Colet J
Cells
. 2020 Sep;
9(10).
PMID: 32992522
Doxorubicin (DOX) is an anticancer drug widely used in oncology, especially for breast cancer. The main limitation of DOX treatment is its cardiotoxicity due to the cumulative dose. Clinically, DOX-induced...
5.
Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem G, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32455924
Treatments of metastatic melanoma underwent an impressive development over the past few years, with the emergence of small molecule inhibitors targeting mutated proteins, such as BRAF, NRAS, or cKIT. However,...
6.
Dallons M, Delcourt M, Schepkens C, Podrecca M, Colet J
Biology (Basel)
. 2020 May;
9(5).
PMID: 32414184
Cardiotoxicity remains a challenging concern both in drug development and in the management of various clinical situations. There are a lot of examples of drugs withdrawn from the market or...
7.
Dallons M, Schepkens C, Dupuis A, Tagliatti V, Colet J
Front Pharmacol
. 2020 Mar;
11:79.
PMID: 32153402
Doxorubicin (DOX) is an anticancer drug widely used in oncology. The main limitation to DOX treatments though is due to the cumulative dose that may lead to cardiotoxicity. Clinically, DOX-induced...
8.
Schepkens C, Dallons M, Dehairs J, Talebi A, Jeandriens J, Drossart L, et al.
Metabolites
. 2019 Nov;
9(11).
PMID: 31744229
In this study, metastatic melanoma, breast, and prostate cancer cell lines were analyzed using a H-NMR-based approach in order to investigate common features and differences of aggressive cancers metabolomes. For...